Andrew Cheng Akero Therapeutics, Inc. (AKRO) insider trading activity

Andrew Cheng is President and CEO of Akero Therapeutics, Inc.. Currently has a direct ownership of 0 shares of AKRO, which is worth approximately $0. The most recent transaction as insider was on Dec 09, 2025, when has been sold 436,837 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

Andrew Cheng Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 09 2025	SELL Sale (or disposition) back to the issuer	-	436,837 Reduced 100.0%	0 Common Stock
Nov 20 2025	SELL Bona fide gift	-	74,538 Reduced 14.58%	436,837 Common Stock
Nov 12 2025	SELL Bona fide gift	-	14,739 Reduced 2.8%	511,375 Common Stock
Oct 10 2025	SELL Open market or private sale	$1,619,400 $53.98 p/Share	30,000 Reduced 5.39%	526,114 Common Stock
Oct 10 2025	BUY Exercise of conversion of derivative security	$596,100 $19.87 p/Share	30,000 Added 5.12%	556,114 Common Stock
Oct 08 2025	BUY Exercise of conversion of derivative security	$32,371 $0.62 p/Share	52,212 Added 9.03%	526,114 Common Stock
Sep 11 2025	SELL Open market or private sale	$77,263 $43.02 p/Share	1,796 Reduced 0.38%	473,902 Common Stock

Sep 10 2025	SELL Open market or private sale	$1,316,100 $43.87 p/Share	30,000 Reduced 5.93%	475,698 Common Stock
Sep 10 2025	BUY Exercise of conversion of derivative security	$196,025 $13.12 p/Share	14,941 Added 2.87%	505,698 Common Stock
Aug 11 2025	SELL Open market or private sale	$1,463,700 $48.79 p/Share	30,000 Reduced 5.76%	490,757 Common Stock
Jul 10 2025	SELL Open market or private sale	$1,534,500 $51.15 p/Share	30,000 Reduced 5.45%	520,757 Common Stock
Jun 30 2025	BUY Grant, award, or other acquisition	$21,244 $23.87 p/Share	890 Added 0.16%	550,757 Common Stock
Jun 18 2025	SELL Open market or private sale	$363,040 $54.84 p/Share	6,620 Reduced 1.19%	549,867 Common Stock
Jun 10 2025	SELL Open market or private sale	$2,044,333 $54.03 p/Share	37,837 Reduced 6.37%	556,487 Common Stock
May 12 2025	SELL Open market or private sale	$1,239,600 $41.32 p/Share	30,000 Reduced 4.81%	594,324 Common Stock
Apr 10 2025	SELL Open market or private sale	$1,056,900 $35.23 p/Share	30,000 Reduced 4.58%	624,324 Common Stock
Mar 12 2025	SELL Open market or private sale	$78,001 $44.88 p/Share	1,738 Reduced 0.26%	654,324 Common Stock
Mar 10 2025	SELL Open market or private sale	$1,260,900 $42.03 p/Share	30,000 Reduced 4.37%	656,062 Common Stock
Feb 10 2025	SELL Open market or private sale	$1,612,200 $53.74 p/Share	30,000 Reduced 4.19%	686,062 Common Stock
Jan 27 2025	SELL Open market or private sale	$1,669,800 $55.66 p/Share	30,000 Reduced 4.02%	716,062 Common Stock
Jan 23 2025	BUY Exercise of conversion of derivative security	$31,000 $0.62 p/Share	50,000 Added 6.28%	746,062 Common Stock
Dec 16 2024	BUY Grant, award, or other acquisition	-	98,500 Added 12.4%	696,062 Common Stock
Dec 10 2024	SELL Open market or private sale	$241,855 $30.79 p/Share	7,855 Reduced 1.3%	597,562 Common Stock
Dec 02 2024	SELL Open market or private sale	$802,250 $32.09 p/Share	25,000 Reduced 3.97%	605,417 Common Stock
Dec 02 2024	BUY Exercise of conversion of derivative security	$527,500 $21.1 p/Share	25,000 Added 3.81%	630,417 Common Stock

Also insider at

VERA

Vera Therapeutics, Inc. Healthcare

ABUS

Arbutus Biopharma Corp Healthcare

Director

Andrew Cheng

President and CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Value

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akero Therapeutics, Inc.

Track Activities on AKRO

Account